International Journal of Infection

Published by: Kowsar

Assessment of the Human Cytomegalovirus UL97 Gene to identify the Resistance to Ganciclovir in Kidney Transplant Recipients in Labbafi-Nejad Hospital

Shahnaz Sali 1 , Farhad Soori 1 and Zahra Arab-Mazar 1 , *
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of Infection: April 2017, 4 (2); e41189
  • Published Online: November 8, 2016
  • Article Type: Research Article
  • Received: August 30, 2016
  • Revised: September 5, 2016
  • Accepted: September 5, 2016
  • DOI: 10.5812/ij.41189

To Cite: Sali S, Soori F, Arab-Mazar Z. Assessment of the Human Cytomegalovirus UL97 Gene to identify the Resistance to Ganciclovir in Kidney Transplant Recipients in Labbafi-Nejad Hospital, Int J Infect. 2017 ; 4(2):e41189. doi: 10.5812/ij.41189.

Abstract
Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Luganini A, Caposio P, Mondini M, Landolfo S, Gribaudo G. New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J Appl Microbiol. 2008; 105(6): 1791-801[DOI][PubMed]
  • 2. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010; 20(4): 202-13[DOI][PubMed]
  • 3. Numata S, Nakamura Y, Imamura Y, Honda J, Momosaki S, Kojiro M. Rapid quantitative analysis of human cytomegalovirus DNA by the real-time polymerase chain reaction method. Arch Pathol Lab Med. 2005; 129(2): 200-4[DOI][PubMed]
  • 4. Boriskin YS, Fuller K, Powles RL, Vipond IB, Rice PS, Booth JC, et al. Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation. J Clin Virol. 2002; 24(1-2): 13-23[PubMed]
  • 5. Sanchez JL, Storch GA. Multiplex, quantitative, real-time PCR assay for cytomegalovirus and human DNA. J Clin Microbiol. 2002; 40(7): 2381-6[PubMed]
  • 6. Hantz S, Michel D, Fillet AM, Guigonis V, Champier G, Mazeron MC, et al. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother. 2005; 49(4): 1580-3[DOI][PubMed]
  • 7. Baldanti F, Silini E, Sarasini A, Talarico CL, Stanat SC, Biron KK, et al. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J Virol. 1995; 69(2): 796-800[PubMed]
  • 8. Baldanti F, Michel D, Simoncini L, Heuschmid M, Zimmermann A, Minisini R, et al. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 2002; 54(1): 59-67[PubMed]
  • 9. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol. 2004; 65(5): 403-9[DOI][PubMed]
  • 10. Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010; 65(12): 2628-40[DOI][PubMed]
  • 11. Prix L, Maierl J, Jahn G, Hamprecht K. A simplified assay for screening of drug resistance of cell-associated cytomegalovirus strains. J Clin Virol. 1998; 11(1): 29-37[PubMed]
  • 12. Pepin JM, Simon F, Dussault A, Collin G, Dazza MC, Brun-Vezinet F. Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures. J Clin Microbiol. 1992; 30(11): 2917-20[PubMed]
  • 13. Gerna G, Sarasini A, Percivalle E, Zavattoni M, Baldanti F, Revello MG. Rapid screening for resistance to ganciclovir and foscarnet of primary isolates of human cytomegalovirus from culture-positive blood samples. J Clin Microbiol. 1995; 33(3): 738-41[PubMed]
  • 14. Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 2000; 44(3): 688-92[PubMed]
  • 15. Chakravarti A, Kashyap B, Matlani M. Cytomegalovirus infection: an Indian perspective. Indian J Med Microbiol. 2009; 27(1): 3-11[PubMed]
  • 16. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev. 1999; 12(2): 286-97[PubMed]
  • 17. Goryainov VA, Kaabak MM, Babenko NN, Platova EN, Aganesov AG, Morozova MM, et al. [Resistant cytomegalovirus infection in related donor kidney allograft recipients]. Ter Arkh. 2016; 88(6): 73-6[PubMed]
  • 18. Hanson KE, Swaminathan S. Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management. Future Microbiol. 2015; 10(10): 1545-8[DOI][PubMed]
  • 19. Lurain NS, Bhorade SM, Pursell KJ, Avery RK, Yeldandi VV, Isada CM, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis. 2002; 186(6): 760-8[DOI][PubMed]
  • 20. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002; 35(7): 866-72[DOI][PubMed]
  • 21. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999; 340(19): 1462-70[DOI][PubMed]
  • 22. Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, et al. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation. 2016; 100(10)-80[DOI][PubMed]
  • 23. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008; 18(4): 233-46[DOI][PubMed]
  • 24. Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 2014; 101: 12-25[DOI][PubMed]
  • 25. Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006; 37(9): 851-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments